EMEA-001533-PIP01-13-M02

Key facts

Invented name
Steglatro
Active substance
Ertugliflozin
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0141/2019
PIP number
EMEA-001533-PIP01-13-M02
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Merck Sharp and Dohme (Europe), Inc. 

Tel. +33 180464738
E-mail: pip.information@merck.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating